Literature DB >> 33608628

Caloric restriction, physical exercise, and CB1 receptor blockade as an efficient combined strategy for bodyweight control and cardiometabolic status improvement in male rats.

Luisa M Lopez Trinidad1, Rosario Martinez1, Garyfallia Kapravelou1, Milagros Galisteo2, Pilar Aranda1, Jesus M Porres3, Maria Lopez-Jurado1.   

Abstract

Obesity is critically associated with the development of insulin resistance and related cardiovascular and kidney diseases. Several strategies for weight loss have been developed but most of them exhibit a post-intervention rebound effect. Here, we aimed to design combined weight-loss strategies of caloric restriction, physical exercise, and administration of a CB1 receptor blocker to inhibit food intake that also accomplish the objectives of lost-weight maintenance and improvement of cardiovascular and renal function. Diet-induced obesity (DIO) was generated in Sprague Dawley rats for 12 weeks to test the effects of single or combined strategies (i.e. caloric restriction, mixed training protocol, and/or administration of appetite suppressant) on caloric intake, body weight, cardiovascular and renal functionality resulting from a weight-loss intervention period of 3 weeks followed by 6 weeks of weight maintenance. Consumption of a high-fat diet (HFD) caused a significant increase in body weight (5th week of the experimental period) and led to the development of insulin resistance, cardiovascular, and renal alterations. The different interventions tested, resulted in a significant body weight loss and improved glucose metabolism, aerobic capacity, electrocardiographic parameters, vascular expression of adhesion molecules and inflammatory mediators, and renal functionality, reaching values similar to the control normocaloric group or even improving them. Successful maintenance of lost weight was achieved along a 6-week maintenance period in addition to adequate health status. In conclusion, the weight-loss and maintenance intervention strategies tested were efficient at reversing the obesity-related alterations in body weight, glucose metabolism, aerobic capacity, cardiovascular and renal functionality. The beneficial action was very consistent for caloric restriction and physical exercise, whereas administration of a CB1 receptor blocker complemented the effects of the prior interventions in some parameters like body weight or aerobic capacity, and showed specific actions in renal status, increasing glomerular filtration rate and diuresis. Overall, the novelty of our study relies on the easy implementation of combined strategies for effective weight management that resulted in significant health benefits.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33608628      PMCID: PMC7896079          DOI: 10.1038/s41598-021-83709-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  69 in total

1.  Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change.

Authors:  Jens C Pruessner; Clemens Kirschbaum; Gunther Meinlschmid; Dirk H Hellhammer
Journal:  Psychoneuroendocrinology       Date:  2003-10       Impact factor: 4.905

Review 2.  The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation.

Authors:  Darleen Sandoval; Daniela Cota; Randy J Seeley
Journal:  Annu Rev Physiol       Date:  2008       Impact factor: 19.318

3.  Effects of a combined intervention with a lentil protein hydrolysate and a mixed training protocol on the lipid metabolism and hepatic markers of NAFLD in Zucker rats.

Authors:  Rosario Martínez; Garyfallia Kapravelou; Ana Donaire; Carlos Lopez-Chaves; Francisco Arrebola; Milagros Galisteo; Samuel Cantarero; Pilar Aranda; Jesus M Porres; María López-Jurado
Journal:  Food Funct       Date:  2018-02-21       Impact factor: 5.396

4.  The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels.

Authors:  Fabio A Iannotti; Cristoforo Silvestri; Enrico Mazzarella; Andrea Martella; Daniela Calvigioni; Fabiana Piscitelli; Paolo Ambrosino; Stefania Petrosino; Gabriella Czifra; Tamás Bíró; Tibor Harkany; Maurizio Taglialatela; Vincenzo Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-03       Impact factor: 11.205

5.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

Authors:  M Bensaid; M Gary-Bobo; A Esclangon; J P Maffrand; G Le Fur; F Oury-Donat; P Soubrié
Journal:  Mol Pharmacol       Date:  2003-04       Impact factor: 4.436

6.  A modified catalase assay suitable for a plate reader and for the analysis of brain cell cultures.

Authors:  G Cohen; M Kim; V Ogwu
Journal:  J Neurosci Methods       Date:  1996-07       Impact factor: 2.390

7.  The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase.

Authors:  Iolanda Esposito; Maria Chiara Proto; Patrizia Gazzerro; Chiara Laezza; Claudia Miele; Anna Teresa Alberobello; Vittoria D'Esposito; Francesco Beguinot; Pietro Formisano; Maurizio Bifulco
Journal:  Mol Pharmacol       Date:  2008-09-18       Impact factor: 4.436

8.  Is the calorie concept a real solution to the obesity epidemic?

Authors:  Salvador Camacho; Andreas Ruppel
Journal:  Glob Health Action       Date:  2017       Impact factor: 2.640

9.  Augmented Insulin and Leptin Resistance of High Fat Diet-Fed APPswe/PS1dE9 Transgenic Mice Exacerbate Obesity and Glycemic Dysregulation.

Authors:  Yi-Heng Lee; Hao-Chieh Hsu; Pei-Chen Kao; Young-Ji Shiao; Skye Hsin-Hsien Yeh; Feng-Shiun Shie; Shu-Meng Hsu; Chih-Wen Yeh; Hui-Kang Liu; Shi-Bing Yang; Huey-Jen Tsay
Journal:  Int J Mol Sci       Date:  2018-08-08       Impact factor: 5.923

Review 10.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04
View more
  2 in total

1.  Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.

Authors:  Tangui Barré; Fabrice Carrat; Clémence Ramier; Hélène Fontaine; Vincent Di Beo; Morgane Bureau; Céline Dorival; Dominique Larrey; Elisabeth Delarocque-Astagneau; Philippe Mathurin; Fabienne Marcellin; Ventzislava Petrov-Sanchez; Carole Cagnot; Patrizia Carrieri; Stanislas Pol; Camelia Protopopescu
Journal:  J Cannabis Res       Date:  2022-06-11

2.  The Impact of CB1 Receptor on Inflammation in Skeletal Muscle Cells.

Authors:  Mansour Haddad
Journal:  J Inflamm Res       Date:  2021-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.